百特醫療 (BAX) 2023 Q4 法說會逐字稿

完整原文

使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主

  • Operator

    Operator

  • Good morning, ladies and gentlemen, and welcome to Baxter International's Fourth Quarter 2023 Earnings Conference Call. (Operator Instructions). As a reminder, this call will be recorded by Baxter and is copyrighted material. It cannot be recorded or rebroadcast without Baxter's permission. If you have any objections, please disconnect at this time. I would now like to turn the call over to Ms. Clare Trachtman, Senior Vice President, Chief Investor Relations Officer at Baxter International. Ms. Trachtman, you may begin.

    各位女士、先生,早安,歡迎參加百特國際(Baxter International)2023 年第四季財報電話會議。(接線員指示)提醒各位,本次電話會議將由百特錄音並受著作權保護。未經百特許可,不得錄音或轉播。如有任何異議,請立即掛線。現在我想把電話交給百特國際資深副總裁兼投資人關係長 Clare Trachtman 女士。Trachtman 女士,請開始。

  • Clare Trachtman - VP of IR

    Clare Trachtman - VP of IR

  • Good morning, and welcome to our fourth quarter 2023 earnings conference call. Joining me today are Joe Almeida, Baxter's Chairman and Chief Executive Officer; and Joel Grade, Baxter's Executive Vice President and Chief Financial Officer.

    各位早安,歡迎參加我們 2023 年第四季財報電話會議。今天與我一同出席的有百特董事長兼執行長 Joe Almeida,以及百特執行副總裁兼財務長 Joel Grade。

  • On the call this morning, we will be discussing Baxter's fourth quarter and full year 2023 financial results along with our financial outlook for 2024. With that, let me start our prepared remarks by reminding everyone that this presentation, including comments regarding our financial outlook for the first quarter and full year 2024, new product development including the impact and status of pending regulatory approvals, the status and potential impact of our ongoing strategic and recent pricing actions, business development, regulatory matters in the macroeconomic environment, including commentary on improving supply chain conditions and evolving customer capital spending trends contain forward-looking statements that involve risks and uncertainties. And of course, our actual results could differ materially from our current expectations.

    今天上午的電話會議中,我們將討論百特 2023 年第四季與全年財務結果,以及我們對 2024 年的財務展望。首先,在開始我們的準備講稿之前,提醒各位,本簡報包含對 2024 年第一季與全年財務展望、新產品開發(包括待核准之監管審批的影響與進度)、我們正在進行的策略性行動與近期定價行動的狀態及其潛在影響、業務發展、監管事項,以及總體經濟環境(包括供應鏈狀況改善與客戶資本支出趨勢演變之評論)等內容,均包含涉及風險與不確定性的前瞻性陳述。當然,我們的實際結果可能與目前預期有重大差異。

  • Please refer to today's press release and our SEC filings for more detailed concerning factors that could cause actual results to differ materially. In addition, on today's call, non-GAAP financial measures will be used to help investors understand Baxter's ongoing business performance. A reconciliation of the non-GAAP financial measures being discussed today to the comparable GAAP financial measures is included in the accompanying investor presentation, along with our earnings release issued this morning, which are both available on our website. Now I'd like to turn the call over to Joe. Joe?

    請參閱今日新聞稿與我們向美國證券交易委員會(SEC)提交的文件,以了解可能導致實際結果與預期有重大差異之因素的更詳細資訊。此外,在今天的電話會議中,我們將使用非 GAAP 財務衡量指標,以協助投資人了解百特持續營運的業務表現。今日討論之非 GAAP 財務衡量指標與可比較之 GAAP 財務衡量指標的調節表,已收錄於隨附的投資人簡報中,並與我們今早發布的財報新聞稿一併提供,兩者皆可於我們網站取得。現在我想把電話交給 Joe。Joe?

  • Jose E. Almeida - Chairman of the Board, President & CEO

    Jose E. Almeida - Chairman of the Board, President & CEO

  • Thank you, Clare, and good morning, everyone. We appreciate you taking the time to join us. I will begin with a brief overview of Baxter's performance for the quarter and the year. After this, I will review our progress against the transformational actions we laid out for you just over a year ago, including the planned separation of our Kidney Care business. I will then turn it over to Joel Grade, who will walk through our results and outlook in more detail. Finally, we will open it up for your questions.

    謝謝你,Clare,各位早安。感謝各位撥冗參與。我將先簡要概述百特本季與本年度的表現。接著,我會回顧我們在一年多前向各位說明的轉型行動之進展,包括規劃中的腎臟照護(Kidney Care)業務分拆。之後我會把電話交給 Joel Grade,他將更詳細說明我們的業績與展望。最後,我們將開放提問。

  • As you saw this morning, Baxter reported strong performance for the fourth quarter of 2023 with top line sales exceeding our projections and bottom line results coming in at the high end of our guidance range. As a reminder, continuing operations exclude the impact of our biopharma solutions business, which we divested at the close of the third quarter. Sales from continuing operations rose 4% on a reported basis ahead of our outlook of 1% to 2% growth. On a constant currency basis, sales increased 3%, also ahead of our guidance, which projected a growth of approximately 1%.

    如各位今早所見,百特 2023 年第四季表現強勁,營收高於我們的預測,獲利表現也落在我們指引區間的高端。提醒各位,持續營運(continuing operations)不包含我們在第三季末完成出售的生物製藥解決方案(biopharma solutions)業務之影響。持續營運的營收以報告基礎(reported basis)年增 4%,優於我們先前預期的 1% 至 2% 成長。以固定匯率(constant currency)計算,營收成長 3%,同樣優於我們指引中約 1% 的成長預估。

  • Strength in the quarter was broad-based with year-over-year growth in the health care systems and technologies, medical products and therapies and pharmaceuticals, which was slightly offset by an expected decline in Kidney Care. Relative to expectations, both of our Chronic Therapies and our Components divisions reported better-than-expected sales. On the bottom line, adjusted earnings per share from continuing operations came in at $0.88 at the top end of our prior guidance range of $0.85 to $0.88.

    本季的強勁表現相當全面,醫療照護系統與科技(Health Care Systems and Technologies)、醫療產品與治療(Medical Products and Therapies)以及製藥(Pharmaceuticals)均較去年同期成長,惟腎臟照護(Kidney Care)如預期下滑,略為抵銷。相較於預期,我們的慢性治療(Chronic Therapies)與零組件(Components)兩個事業部的營收均優於預期。在獲利方面,持續營運的調整後每股盈餘(adjusted EPS)為 0.88 美元,位於先前 0.85 至 0.88 美元指引區間的上緣。

  • Our fourth quarter results further reinforced our building momentum. In 2023, we focused on consistently meeting and/or exceeding our financial outlook, particularly in light of the significant supply chain and macro environmental challenges we encountered during 2022. As a testament to this focus, over the course of 2023, we were able to deliver sequential improvement every quarter, and we believe this performance provides us with a solid foundation to build off in 2024.

    我們第四季的結果進一步強化了我們正在累積的動能。2023 年,我們專注於持續達成並/或超越財務展望,特別是在 2022 年遭遇顯著供應鏈與總體環境挑戰的背景下。作為此一專注的證明,2023 年期間我們每一季都實現逐季改善(sequential improvement),我們相信這樣的表現為 2024 年奠定了穩固的基礎。

  • Turning to the full year sales from continuing operations of $14.8 billion advanced 2% on a reported basis and 3% on a constant currency basis, driven by sales growth for all of our segments at constant currency rates.

    再看全年,持續營運營收為 148 億美元,以報告基礎年增 2%,以固定匯率計算年增 3%,主要由我們所有事業部在固定匯率下的營收成長所帶動。

  • First, looking at the constant currency sales growth in the segment set to comprise our future Baxter portfolio following the planned Kidney Care separation. Sales in Healthcare Systems & Technologies were up 7% in the fourth quarter and 3% for the year. Medical Products and Therapy sales rose 4% in both the quarter and for the year, and sales in Pharmaceuticals were up 7% for both the quarter and the year.

    首先,觀察在規劃完成腎臟照護分拆後、將構成未來百特投資組合之事業部的固定匯率營收成長。醫療照護系統與科技(Healthcare Systems & Technologies)第四季成長 7%,全年成長 3%。醫療產品與治療(Medical Products and Therapy)營收在本季與全年皆成長 4%,製藥(Pharmaceuticals)營收在本季與全年皆成長 7%。

  • Performance in these segments was filled by strong execution across our commercial and manufacturing teams. New product launches increased the availability of electromechanical component and a more stable supply chain and macroeconomic environment relative to the significant volatility experienced last year.

    這些事業部的表現,來自我們商業與製造團隊的強勁執行力、新產品上市提升了機電零組件(electromechanical component)的供應可得性,以及相較去年顯著波動而言更為穩定的供應鏈與總體經濟環境。

  • With respect to hospital CapEX spending, while we still believe there may be pockets of softer spending, we are encouraged by the sequential improvement we experienced every quarter in 2023 within our Care and Connectivity Solutions division. Our Kidney Care segment, which will be called Vantive post separation, declined 1% in the quarter and grew 1% for the year at constant rates.

    就醫院資本支出(CapEX)而言,雖然我們仍認為部分領域可能出現較疲弱的支出,但我們對 2023 年在 Care and Connectivity Solutions 事業部每一季所呈現的逐季改善感到鼓舞。我們的腎臟照護事業部在分拆後將命名為 Vantive,本季以固定匯率計算下滑 1%,全年以固定匯率計算成長 1%。

  • Strong growth in Acute Therapies was offset by flat growth in chronic therapies, reflecting a difficult year-over-year comparison due to certain discrete items that benefited sales in the prior year as well as lower sales in China due to the impact of government based procurement initiatives and the lower patient census due to the pandemic.

    急性治療(Acute Therapies)的強勁成長,被慢性治療(chronic therapies)持平所抵銷;這反映了去年同期因若干一次性因素帶動營收而形成的艱難比較基期,以及因政府主導的集中採購措施影響與疫情導致病患人數(patient census)下降,使中國地區銷售較低。

  • The underlying state of the Kidney Care business continues to improve and the momentum we are building is evident. Among key indicators, we are seeing renewed growth in the peritoneal dialysis patient population following the earlier impact of pandemic-driven mortality issues. Our strategic rationale and hypothesis for an independent Kidney Care business remains as strong as ever. Our team is executing and gearing up for a successful separation this year.

    腎臟照護業務的基本面持續改善,我們正在建立的動能也相當明顯。以關鍵指標而言,在先前疫情導致死亡率上升的影響過後,我們看到腹膜透析(peritoneal dialysis)病患族群重新恢復成長。我們對腎臟照護業務獨立運作的策略理由與假設依然非常堅實。我們的團隊正持續執行,並為今年成功分拆做準備。

  • Given overall business performance and environmental dynamics, I'm optimistic as we look ahead to the prospects for both Baxter and Vantive as separate entities. Our solid financial performance was achieved in parallel with meaningful progress against the strategic priorities we announced to open 2023. We kicked off the year with an urgency to rethink both the scope and velocity of our transformation. Since then, our team delivered executing on a range of goals to position a separated Baxter and Vantive for a new era of enhanced patient and shareholder impact, enabled by heightened strategic clarity, operational efficiency and innovation.

    綜合整體業務表現與環境動態,展望未來,對百特與 Vantive 作為獨立公司各自的前景,我抱持樂觀。我們在取得穩健財務表現的同時,也在 2023 年初所宣布的策略優先事項上取得實質進展。我們以高度急迫感啟動新年度,重新思考轉型的範疇與速度。自那之後,我們的團隊在一系列目標上交付成果,使分拆後的百特與 Vantive 能在更清晰的策略方向、更高的營運效率與創新能力支持下,邁向提升病患與股東影響力的新時代。

  • We realigned our businesses into newly streamlined simplified operating model based on globally integrated business segments. Each segment is led by a seasoned and knowledgeable executive who has profit and loss accountability, inclusive of dedicated commercial research and development, manufacturing, supply chain and functional teams. We are already seeing the benefits of improved line of sight to our customers and greater agility to recognize and capture growth opportunities.

    我們依據全球整合的事業部架構,將業務重新調整為更精簡、簡化的營運模式。每個事業部皆由資深且具專業的主管領導,並對損益(profit and loss)負責,涵蓋專屬的商業、研發、製造、供應鏈與各項職能團隊。我們已開始看到效益,包括對客戶需求更清楚的掌握,以及更高的敏捷性,以辨識並把握成長機會。

  • We completed the divestiture of our biopharma solutions business at the close of Q3, which further allowed us to streamline our strategic focus on our core businesses. We are in the process of utilizing the after-tax proceeds of approximately $3.7 billion to pay down debt in line with our stated capital allocation priorities, including $2.8 billion of repayments in the fourth quarter.

    我們在第三季末完成出售生物製藥解決方案(biopharma solutions)業務,進一步使我們能將策略重心精簡聚焦於核心業務。我們正依照既定的資本配置優先順序,運用約 37 億美元的稅後所得款項來償還債務,其中第四季已償還 28 億美元。

  • Finally, we continue to make progress towards separating Vantive out of Baxter. As we have consistently stated, we believe this separation will ultimately empower both companies to pursue their own unique strategic and investment priorities. Many of you had the opportunity to meet designated Vantive's CEO, Chris Toth, at the JPMorgan conference last month.

    最後,我們持續推進將 Vantive 自百特分拆的工作。如我們一再表示,我們相信此一分拆最終將使兩家公司都能追求各自獨特的策略與投資優先事項。上個月在摩根大通(JPMorgan)會議上,許多人也有機會與已指定的 Vantive 執行長 Chris Toth 會面。

  • Chris has been hard at work building out his organization, meeting customers and setting near-term and long-term strategies. Among recent developments, Chris has onboarded Matthew Harbaugh as designated Vantive CFO. Many of you may know Matt from his days as CFO at NuVasive.

    Chris 一直努力不懈地建構其組織、拜訪客戶,並制定短期與長期策略。在近期進展方面,Chris 已延攬 Matthew Harbaugh 擔任指定的 Vantive 財務長(CFO)。許多人可能認識 Matt,因為他曾在 NuVasive 擔任財務長。

  • Meanwhile, we continue to hit key separation milestones across operational, legal, regulatory, supply chain IT domains. In summary, 2023 was a year of rebuilding and renewing our momentum. We made significant progress on an ambitious slate of strategic initiatives coupled with solid financial performance while never losing focus on our foundational commitments to our customers and patients.

    同時,我們持續在營運、法律、法規、供應鏈與 IT 等領域達成關鍵分拆里程碑。總結而言,2023 年是重建並重振動能的一年。我們在一系列具雄心的策略性計畫上取得重大進展,並展現穩健的財務表現,同時始終不忘對客戶與病患的基礎承諾。

  • Additionally, we have created a new potential to embrace more exciting opportunities to come. I do not take the accomplishments of this past year for granted. I want to thank and recognize all of the employees whose hard work and commitment helped us to achieve our objectives. I have never been more impressed by what a team could achieve in a single year, and that is why I'm so energized by our potential to seize on opportunities we have created together. Now we turn it over to Joel for a closer look at our fourth quarter and full year 2023 performance as well as our 2024 outlook.

    此外,我們也創造了新的可能性,以迎接未來更令人振奮的機會。我不會把過去一年的成就視為理所當然。我想感謝並表揚所有員工,正是他們的辛勤付出與投入,協助我們達成目標。我從未如此深刻地感受到一個團隊能在一年內完成的成就,這也是為什麼我對我們把握共同創造之機會的潛力充滿熱情。接下來把時間交給 Joel,請他更深入說明我們 2023 年第四季與全年表現,以及 2024 年展望。

  • Joel T. Grade - Executive VP & CFO

    Joel T. Grade - Executive VP & CFO

  • Thanks, Joe, and good morning, everyone. I'm happy to be joining the call this morning to provide some additional details on Baxter's fourth quarter and full year 2023 financial performance, as well as commentary on our financial outlook for 2024.

    謝謝你,Joe,各位早安。我很高興今天早上能加入這通電話會議,提供 Baxter 2023 年第四季與全年財務表現的更多細節,並就我們 2024 年的財務展望提出評論。

  • As Joe mentioned, we are pleased with our fourth quarter results, which represented another step forward in our ongoing business transformation. Fourth quarter 2023 global sales of $3.9 billion increased 4% on a reported basis and 3% on a constant currency basis and compared favorably to our previously issued guidance of 1% to 2% reported and approximately 1% constant currency. Outperformance in the quarter benefited from better-than-expected sales in many product categories and particularly in chronic therapies and drug compounding.

    如 Joe 所提,我們對第四季結果感到滿意,這代表我們持續推動的業務轉型又向前邁進一步。2023 年第四季全球銷售額為 39 億美元,按報告基礎成長 4%,按固定匯率基礎成長 3%,且優於我們先前發布的指引:按報告基礎成長 1% 至 2%,按固定匯率約成長 1%。本季優於預期的表現,受惠於多個產品類別的銷售優於預期,尤其是慢性治療與藥品調配(drug compounding)。

  • As compared to the prior year period, we reported solid quarterly growth in health care systems and technologies, pharmaceuticals and medical products and therapies. And collectively, sales for these 3 businesses, which will comprise Baxter post the separation, increased approximately 5%. As expected, Kidney Care sales declined slightly in the quarter due to the factors Joe mentioned earlier.

    與去年同期相比,我們在醫療照護系統與科技、製藥,以及醫療產品與治療等業務均呈現穩健的季度成長。合計而言,這三項業務(在分拆後將構成 Baxter 的主體)的銷售額約成長 5%。如預期,腎臟照護(Kidney Care)本季銷售略為下滑,原因如 Joe 先前所述。

  • On the bottom line, adjusted earnings totaled $0.88 per share, increasing 13% versus the prior year period. These results reflect the ongoing operational improvements we are recognizing both commercially as well as within our supply chain network as that team successfully executes on its margin improvement programs. Lower interest expense and a benefit from foreign exchange also contributed favorably to the quarter partially offset by the impact of a higher tax rate compared to the prior year.

    在獲利方面,調整後每股盈餘為 0.88 美元,較去年同期成長 13%。這些結果反映我們持續的營運改善,無論在商業端或供應鏈網路內皆有所體現,供應鏈團隊也成功執行其改善毛利的計畫。利息費用降低以及外匯帶來的利益亦對本季有正面貢獻,但部分被較去年同期更高的稅率影響所抵銷。

  • Adjusted earnings per share for the quarter came in at the high end of our expected range of $0.85 to $0.88 per share, primarily driven by better sales and operational performance.

    本季調整後每股盈餘落在我們預期區間 0.85 至 0.88 美元的高端,主要由更佳的銷售與營運表現所帶動。

  • Now I'll walk through performance by our reportable segments. Commentary regarding sales growth will reflect growth at constant currency rates. Sales in our Medical Products and Therapies segments were $1.3 billion, increasing 4%. Full year 2023 sales totaled $5 billion also advancing 4%. Within Medical products and therapies, fourth quarter sales from our Infusion Therapies and Technologies division totaled $1 billion and increased 4%.

    接下來我將說明各可報告部門的表現。關於銷售成長的評論將以固定匯率計算的成長為準。我們的醫療產品與治療(Medical Products and Therapies)部門本季銷售額為 13 億美元,成長 4%。2023 年全年銷售額為 50 億美元,同樣成長 4%。在醫療產品與治療之中,我們輸注治療與科技(Infusion Therapies and Technologies)事業部第四季銷售額為 10 億美元,成長 4%。

  • Sales in the quarter benefited from strength in our IV Solutions portfolio, particularly outside the United States as well as solid performance in our Infusion System portfolio. Sales from Advanced Surgery totaled $278 million and grew 6%, coming in ahead of expectations and reflecting strong growth internationally.

    本季銷售受惠於我們靜脈注射(IV)溶液產品組合的強勁表現,尤其是在美國以外地區,以及我們輸注系統產品組合的穩健表現。先進外科(Advanced Surgery)銷售額為 2.78 億美元,成長 6%,優於預期,並反映國際市場的強勁成長。

  • For our Healthcare Systems & Technologies, or HST segment, sales in the quarter were $795 million and increased 7%. Full year 2023 sales totaled $3 billion, advancing 3%. Within the HST segment, sales in our Care and Connectivity Solutions, or CCS division were $492 million, increasing 11%. Performance in the quarter benefited from double-digit growth in all key product categories within the division, including our care communications, surgical solutions and patient support systems product offerings. Growth in the quarter was partially offset by lower contribution from rental revenues.

    在醫療照護系統與科技(Healthcare Systems & Technologies,HST)部門,本季銷售額為 7.95 億美元,成長 7%。2023 年全年銷售額為 30 億美元,成長 3%。在 HST 部門中,我們照護與連結解決方案(Care and Connectivity Solutions,CCS)事業部銷售額為 4.92 億美元,成長 11%。本季表現受惠於該事業部所有關鍵產品類別皆呈現兩位數成長,包括照護通訊、手術解決方案與病患支援系統等產品。惟本季成長部分被租賃收入貢獻下降所抵銷。

  • Fourth quarter United States orders within CCS continued to improve sequentially, but notably also grew on a year-over-year basis for the first time in 2023. While we are encouraged by the improvement in capital spending we've seen from our U.S. hospital customers, we continue to believe there may still be select pockets of cautiousness in the marketplace.

    CCS 在美國的第四季訂單持續呈現逐季改善,且值得注意的是,2023 年首次出現年對年成長。雖然我們對美國醫院客戶資本支出改善的趨勢感到鼓舞,但我們仍認為市場上可能仍存在部分較為謹慎的區域。

  • Front Line Care sales in the quarter were $303 million, increasing 2%. Given the improvements in electromechanical component availability over the course of 2023, we're able to successfully address our elevated backlog and exited the year at more normalized levels. Sales in our Pharmaceuticals segment were $596 million, increasing 7%. For the full year, sales were $2.2 billion, also advancing 7%.

    第一線照護(Front Line Care)本季銷售額為 3.03 億美元,成長 2%。鑑於 2023 年期間機電元件供應可得性改善,我們得以成功消化偏高的積壓訂單,並在年底將水位降至較正常的水平。製藥(Pharmaceuticals)部門本季銷售額為 5.96 億美元,成長 7%。全年銷售額為 22 億美元,同樣成長 7%。

  • Performance in the quarter reflected double-digit growth in our U.S. injectables portfolio driven by new product launches as well as continued strong demand for our services within our drug compounding portfolio internationally.

    本季表現反映我們美國注射劑產品組合在新產品上市帶動下呈現兩位數成長,同時我們在國際市場的藥品調配(drug compounding)產品組合之服務需求亦持續強勁。

  • Other sales, which represent sales not allocated to a segment and primarily include sales of products and services provided directly through certain of our manufacturing facilities were $18 million and declined 58% during the quarter, in line with our expectations. This lower level of sales reflects reduced demand for certain contract manufacturing volumes and the termination of a royalty arrangement.

    其他銷售(Other sales)係指未分配至部門的銷售,主要包括透過我們部分製造設施直接提供之產品與服務的銷售額,本季為 1,800 萬美元,下降 58%,符合我們的預期。此較低的銷售水準反映特定委託製造(contract manufacturing)產量需求下降,以及一項權利金安排的終止。

  • Moving on to Kidney Care. Sales in the quarter were $1.2 billion and declined 1%. Full year 2023 sales totaled $4.5 billion and increased 1%. Within Kidney Care, global sales for chronic therapies were $950 million, declining 3%, though as mentioned earlier, came in better than expected. Sales growth in the quarter was impacted by a difficult comparison to the prior year period, which included certain discrete items in the U.S. that totaled approximately $25 million.

    接著談腎臟照護(Kidney Care)。本季銷售額為 12 億美元,下降 1%。2023 年全年銷售額為 45 億美元,成長 1%。在腎臟照護中,慢性治療(chronic therapies)全球銷售額為 9.5 億美元,下降 3%,但如先前所述,仍優於預期。本季銷售成長受到與去年同期相比的高基期影響;去年同期在美國包含若干一次性項目,合計約 2,500 萬美元。

  • Finally, performance in chronic therapies continues to be impacted by lower sales in China due to certain government-based procurement initiatives and a lower patient census due to the pandemic. We estimate that collectively, these country-specific factors negatively impacted sales by approximately $35 million in the quarter.

    最後,慢性治療的表現仍受到中國銷售下滑的影響,原因包括特定政府主導的採購措施,以及因疫情導致的病患人數(patient census)下降。我們估計,合計而言,這些國別因素在本季對銷售造成約 3,500 萬美元的負面影響。

  • Sales in our Acute Therapies business were $206 million, representing growth of 6% with strength across most regions, including double-digit growth in the United States, where we've now rebased this business following the pandemic-related benefits we previously experienced.

    我們急性治療(Acute Therapies)業務本季銷售額為 2.06 億美元,成長 6%,多數地區皆呈現強勁表現,包括美國的兩位數成長;在美國市場,我們已在先前疫情相關紅利消退後,重新校準(rebased)此業務的基期。

  • Now moving through the rest of the P&L. Our adjusted gross margin totaled 42% and represented an increase of 80 basis points over the prior year. The year-over-year improvement in gross margin primarily reflects the stabilization of macroeconomic factors and inflationary pressures that previously contributed to higher cost for raw materials, overhead and labor that impacted our margins earlier in the year. Margin improvement in the quarter also benefited from pricing initiatives in select markets and ongoing margin improvement programs in our integrated supply chain network.

    接下來說明損益表(P&L)的其餘項目。我們的調整後毛利率為 42%,較去年同期提升 80 個基點。毛利率年對年改善主要反映宏觀經濟因素與通膨壓力趨於穩定;先前這些因素推升原物料、製造費用與人力成本,並在年初對我們的毛利造成影響。本季毛利改善亦受惠於部分市場的定價措施,以及我們整合供應鏈網路中持續推動的毛利改善計畫。

  • Performance for the quarter was in line with our expectations as top line outperformance in the quarter was driven by lower-margin divisions, which drove a slightly negative gross profit mix in the quarter. Adjusted SG&A totaled $829 million or 21.3 as a percentage of sales, an increase of 20 basis points versus the prior year period.

    本季表現符合我們的預期;由於本季營收端的優於預期主要來自較低毛利的事業部,導致本季毛利組合(gross profit mix)略為不利。調整後銷售、一般及行政費用(SG&A)為 8.29 億美元,占銷售額比重為 21.3%,較去年同期增加 20 個基點。

  • Performance in the quarter benefited from our ongoing transformation initiatives to enhance operational efficiencies, offset by higher bonus accruals under our annual employee incentive compensation plans compared to the prior year, and select investments in sales and marketing initiatives.

    本季表現受惠於我們持續推動的轉型計畫以提升營運效率,但部分被以下因素抵銷:相較去年,我們依年度員工激勵薪酬計畫提列的獎金準備較高,以及在銷售與行銷計畫上的部分投資。

  • Adjusted research and development spending in the quarter totaled $172 million, and represented 4.4% as a percentage of sales, increasing 20 basis points versus the prior year. We have ramped up our R&D efforts, particularly increasing our investments in advancing new products across the portfolio and, like SG&A, R&D expenses include the impact of higher employee incentive accruals as compared to the prior year period. These factors resulted in an adjusted operating margin of 16.2%, an increase of 30 basis points.

    本季經調整後的研發支出合計為1.72億美元,占銷售額的4.4%,較去年同期增加20個基點。我們已加大研發投入,特別是增加對推進產品組合中新產品開發的投資;且與SG&A相同,研發費用亦包含相較去年同期更高的員工激勵獎金提列之影響。上述因素使經調整後的營業利益率達16.2%,提高30個基點。

  • Overall, we are very pleased with the second half margin expansion we're able to realize with operating margins improving approximately 300 basis points in the second half of the year as compared to the first half of 2023. Net interest expense totaled $73 million in the quarter, a decrease of $44 million versus the prior year and down $55 million sequentially, driven by debt repayment of approximately $2.8 billion associated with the utilization of the proceeds from our BPS divestiture. We plan to continue to repay debt in 2024, consistent with our stated capital allocation priorities.

    整體而言,我們對下半年可實現的利潤率擴張感到非常滿意;與2023年上半年相比,2023年下半年營業利益率約提升300個基點。本季淨利息費用合計7,300萬美元,較去年同期減少4,400萬美元,較前一季減少5,500萬美元,主要受惠於償還約28億美元債務,該償債資金來自我們出售BPS業務所得款項的運用。我們計畫於2024年持續償還債務,與我們既定的資本配置優先順序一致。

  • Adjusted other nonoperating income totaled $11 million in the quarter compared to an expense of $11 million in the prior year period. Year-over-year improvement was largely due to lower foreign exchange losses incurred as compared with the prior year period. The adjusted tax rate in the quarter was 21.0% compared to 14.6% in the prior year period. The year-over-year increase is primarily driven by statute expirations on certain tax positions benefiting the prior year period.

    本季經調整後的其他非營業收入合計1,100萬美元,而去年同期為1,100萬美元的費用。年對年改善主要來自相較去年同期所發生的外匯損失較低。本季經調整後的有效稅率為21.0%,去年同期為14.6%。年對年上升主要是因去年同期受惠於部分稅務立場之法定期限到期(statute expirations)。

  • The tax rate in the quarter came in higher than expected, primarily driven by changes in geographic earnings mix. And as previously mentioned, adjusted earnings totaled $0.88 and increased 13% versus the prior year, primarily driven by better-than-expected sales and operational efficiencies as well as lower interest expense, partially offset by the tax rate in the quarter.

    本季稅率高於預期,主要受地區獲利組合變動所致。如先前所述,經調整後每股盈餘為0.88美元,較去年同期增加13%,主要由優於預期的銷售表現與營運效率提升,以及較低的利息費用所帶動,但部分被本季較高的稅率所抵銷。

  • For the full year, Baxter's adjusted earnings from continuing operations decreased 14% to $2.60 per diluted share, reflecting the impact of higher cost of goods sold driven primarily by the macro environmental factors we previously discussed, greater annual employee bonus accruals as well as increased nonoperating expenses. These factors were partially offset by our operational and supply chain savings initiatives.

    就全年而言,Baxter持續營運之經調整後盈餘下降14%,至每股稀釋後2.60美元,反映銷貨成本上升之影響(主要由我們先前討論的總體環境因素所驅動)、年度員工獎金提列增加,以及非營業費用上升。上述因素部分被我們的營運與供應鏈節省計畫所抵銷。

  • With respect to cash flow, we generated free cash flow for the year of over $1 billion from continuing operations compared to $411 million in the prior year period. Going forward, cash flow generation and, in particular, improving our working capital metrics is a key priority, both for me and the Baxter team.

    就現金流而言,我們全年自持續營運產生的自由現金流超過10億美元,較去年同期的4.11億美元大幅增加。展望未來,現金流創造,尤其是改善營運資金指標,是我與Baxter團隊的關鍵優先事項。

  • To close on our full year results, we are pleased with our operating performance through 2023, which reflected both consistent progress and building momentum. And it is important to note that our teams were able to achieve this performance while also making meaningful progress against our strategic initiatives designed to enhance our future performance and drive incremental value for all stakeholders. We look forward to building on that positive momentum as we enter 2024.

    在總結全年業績時,我們對2023年的營運表現感到滿意,這反映了持續的進展與動能的累積。值得注意的是,我們的團隊在達成上述表現的同時,也在推動策略性計畫方面取得實質進展,這些計畫旨在提升未來表現並為所有利害關係人創造增量價值。我們期待在邁入2024年之際,延續這股正向動能。

  • Let me conclude my remarks by discussing our outlook for the first quarter and full year 2024, including some key assumptions underpinning the guidance.

    最後,我將說明我們對2024年第一季與全年之展望,包括支撐指引的一些關鍵假設。

  • For full year 2024, Baxter expects total sales growth of 2% on both a reported and constant currency basis, as the impact from foreign exchange is currently expected to be minimal on a full year basis. Constant currency sales guidance for the full year by reportable segments is as follows: for Medical Products and Therapies, we expect sales growth of 3% to 4%; sales in our Healthcare Systems and Technology segments are expected to increase approximately 3%; we expect Pharmaceuticals sales growth of 4% to 5%; collectively, sales for these remaining Baxter businesses are expected to increase 3% to 4% in 2024; for Kidney Care, we expect sales growth to decline 1% to 2% as compared to 2023.

    就2024年全年而言,Baxter預期總銷售額成長2%,無論以報告基礎或以固定匯率基礎計算皆為2%,因目前預期外匯對全年影響極小。按可報告部門(reportable segments)之全年固定匯率銷售指引如下:醫療產品與治療(Medical Products and Therapies)預期銷售成長3%至4%;醫療照護系統與科技(Healthcare Systems and Technology)部門預期銷售約成長3%;製藥(Pharmaceuticals)預期銷售成長4%至5%;合計而言,這些其餘Baxter業務在2024年預期成長3%至4%;腎臟照護(Kidney Care)方面,預期銷售成長較2023年下降1%至2%。

  • Factors impacting year-over-year growth are primarily driven by select market and product exits in connection with our margin expansion initiatives for this segment which we estimate will negatively impact sales by approximately $150 million. Additionally, the incremental impact from the ongoing government procurement initiatives in China is expected to total approximately $70 million in 2024.

    影響年對年成長的因素,主要來自為推動該部門利潤率擴張計畫而進行的特定市場與產品退出,我們估計將使銷售額減少約1.5億美元。此外,中國持續推動的政府採購計畫所帶來的增量影響,預期在2024年合計約為7,000萬美元。

  • Now turning to our outlook for other P&L line items. We expect adjusted operating margin to increase by at least 50 basis points in 2024. We expect our nonoperating expenses, which include net interest expense and other income and expense to total approximately $350 million in aggregate during 2024. We anticipate a full year adjusted tax rate between 22.0% and 22.5%, which reflects an approximate 100 basis point impact to the 2024 tax rate from the implementation of Pillar Two. We expect our diluted share count to increase slightly and average 510 million shares for the year.

    接著談其他損益表(P&L)項目之展望。我們預期2024年經調整後的營業利益率至少提升50個基點。我們預期非營業費用(包含淨利息費用及其他收入與費用)在2024年合計約為3.5億美元。我們預估全年經調整後有效稅率介於22.0%至22.5%,其中反映「第二支柱」(Pillar Two)實施對2024年稅率約100個基點的影響。我們預期稀釋後流通股數將小幅增加,全年平均為5.10億股。

  • Based on all these factors, we anticipate full year adjusted earnings, excluding special items, of $2.85 to $2.95 per diluted share. Specific to the first quarter of 2024, we expect global sales growth of approximately 1% on a reported basis and 1% to 2% on a constant currency basis. And we expect adjusted earnings, excluding special items, of $0.59 to $0.62 per diluted share. With that, we can now open up the call for Q&A.

    綜合上述因素,我們預期全年經調整後盈餘(不含特殊項目)為每股稀釋後2.85至2.95美元。就2024年第一季而言,我們預期全球銷售額以報告基礎約成長1%,以固定匯率基礎成長1%至2%。我們亦預期經調整後盈餘(不含特殊項目)為每股稀釋後0.59至0.62美元。接下來我們開放Q&A。

  • Operator

    Operator

  • (Operator Instructions)

    (接線員指示)

  • I would like to remind participants that this call is being recorded, and a digital replay will be available on the Baxter International website for 60 days at www.baxter.com.

    提醒各位與會者,本次電話會議將被錄音,並將於Baxter International網站提供數位重播,為期60天,網址為www.baxter.com。

  • Our first question is from Travis Steed of Bank of America Securities.

    第一個問題來自美國銀行證券(Bank of America Securities)的Travis Steed。

  • Travis Lee Steed - MD

    Travis Lee Steed - MD

  • I'll go ahead and ask both of mine upfront. One, on the revenue side. You talked about sequential improvement every quarter and when you look at the 2024 revenue guidance of 2%, maybe think through like some of the areas that could improve over the course of the year, where there could be some conservatism built then to the '24 and how to think about the cadence of the year? And the second question really is on margins, if you think about the 50 basis point margin guidance. Curious what some of the underlying assumptions are on FX and inflationary pressures and stuff like that?

    我先把兩個問題一起問。第一個是營收面:你提到每一季都有逐季改善;當你看2024年2%的營收指引時,能否談談今年過程中有哪些領域可能改善、哪些地方在2024年的指引中可能帶有較保守的假設,以及該如何看待全年節奏?第二個問題是利潤率:若以50個基點的利潤率指引來看,想請教其中對匯率、通膨壓力等的主要假設是什麼?

  • Joel T. Grade - Executive VP & CFO

    Joel T. Grade - Executive VP & CFO

  • Travis, this is Joel. Thank you for the call. So I guess I'd say a couple of things. First of all, we feel very good about the momentum in our business. I think we had a -- we saw a solid fourth quarter. We are pleased with some of the results that we have heading into this year. And I think the revenue guidance that you see, if you think about overall, the business outside of Kidney is growing 3% to 4% that we have, as we've talked about our forecast.

    Travis,我是Joel。謝謝你的提問。我想我會說幾點。首先,我們對業務動能感到非常有信心。我認為第四季表現穩健;對於我們在進入今年時所呈現的一些成果感到滿意。而你看到的營收指引,若從整體來看,除腎臟業務之外的其他業務如我們先前談到的預測,成長約為3%至4%。

  • With Kidney itself, if you think about that, we actually have about -- there's about $150 million of purposeful business that we're actually exiting products, we're exiting markets. And so if you actually factor that into that equation, again, we're up over that 3% number for the year, which I think is great.

    至於腎臟業務本身,如果你這樣看,我們其實大約有——約1.5億美元是我們有意識地退出的業務,包括退出某些產品、退出某些市場。因此若把這點納入計算,同樣地,我們全年其實會高於3%的那個數字,我認為這很棒。

  • If you think about the full year guidance itself, a couple some of that strong sales performance with the fact that we're actually expanding our margins by over 50 basis points and we're actually leading to double-digit BPS growth. We feel really good about that.

    如果你看全年指引本身,結合部分強勁的銷售表現,以及我們將利潤率擴張超過50個基點,並帶動BPS(Baxter產品解決方案)實現雙位數成長,我們對此感覺非常好。

  • Now on the margin side, to answer the question you asked, I think the main puts and takes in that -- the main part is the operational cost improvements in that. There's a big piece of that from also pricing, from volume. And again, so I think some of the things that you have in there are some of the key assumptions on the margins.

    至於利潤率面,回答你剛才的問題,我認為其中主要的增減因素——最主要的部分是營運成本改善。此外也有很大一部分來自定價與銷量。因此,我認為你在其中看到的,就是一些關於利潤率的關鍵假設。

  • I think in all those areas, we feel good about the opportunities again to build on momentum we've had. If you remember in the last quarter, our HST business, we're very pleased with the momentum we had from a sales perspective in Q4, and we do anticipate that heading into the year as well. So again, lots of good stuff there, but I'll pause there for any other points that (inaudible).

    我認為在所有這些領域,我們對再次把握機會、在既有動能上持續推進都感到很有信心。若你還記得上一季,我們的 HST 業務,從銷售角度來看,我們對第四季(Q4)所展現的動能非常滿意,而且我們也預期這股動能會延續到今年。因此,這裡確實有很多正面的進展,但我先暫停一下,看看是否還有其他要點(聽不清)。

  • Clare Trachtman - VP of IR

    Clare Trachtman - VP of IR

  • Yes. Travis, I'll add in a little bit here. So in terms of the cadence, I would say if we think about just the shape of the P&L, I think sales will be relatively -- you'll see some slight acceleration in the second half of the year. But in terms of margin expansion, you are going to see first half margin expansion more outsized than you will see in the second half, obviously, just given the comp, and similarly, you'll see that on earnings growth. So earnings growth in the first half of the year will be very strong.

    是的。Travis,我在這裡補充一點。就節奏而言,如果我們只看損益表(P&L)的走勢,我認為銷售相對而言——你會看到下半年會有些微加速。但就毛利率擴張而言,你會看到上半年的毛利率擴張幅度會比下半年更顯著,這顯然是因為比較基期(comp)的關係;同樣地,獲利成長也會呈現類似情況。因此,今年上半年的獲利成長會非常強勁。

  • Your question on FX, Travis, was FX is negative on margins for the year, about 40 basis points of an impact on our operating margins on a year-over-year basis.

    你關於外匯(FX)的問題,Travis,是指外匯對今年的毛利率為負面影響;以年對年來看,外匯約會對我們的營業利益率造成 40 個基點的影響。

  • Operator

    Operator

  • Robert Marcus of JPMorgan has a question.

    摩根大通(JPMorgan)的 Robert Marcus 有一個問題。

  • Unidentified Analyst

    Unidentified Analyst

  • This is [Allen] on for Robbie. I had a question on some of the strength that we saw in the fourth quarter and a little bit of the softer first quarter guide. Was there any pull forward of sales into this quarter? You talked about how you recovered some of the backlogs. So I expect some of that drove the outsized strength. But also just looking at first quarter, given what we view as an easy comp, why aren't you able to put up a better growth number at the start of the year? How much of that is conservatism versus realism?

    我是代替 Robbie 的 [Allen]。我想問一下第四季我們看到的一些強勁表現,以及第一季指引稍微偏弱的部分。是否有任何銷售被提前拉到本季?你們提到已經消化了一些積壓訂單,所以我預期其中一部分推動了超預期的強勁表現。但另外,單看第一季,考量到我們認為比較基期相對容易,為什麼年初無法交出更好的成長數字?其中有多少是保守、又有多少是更貼近現實的判斷?

  • Clare Trachtman - VP of IR

    Clare Trachtman - VP of IR

  • Yes. So what I would say is probably one of the biggest drivers in terms of the quarterly cadence is within our HST business, where sales do ramp over the course of the year. So very similar to what we saw in 2023. You will see our HST business have growth -- accelerated growth in the second half of the year as compared to the first half of the year. So I think that's probably one of the bigger drivers in terms of the first quarter guidance.

    是的。我會說,就季度節奏而言,最大的驅動因素之一可能在我們的 HST 業務,因為該業務的銷售會在一年當中逐步拉升。這與我們在 2023 年看到的情況非常相似。你會看到我們的 HST 業務在下半年的成長——相較於上半年會是加速成長。因此,我認為這大概是第一季指引中較大的驅動因素之一。

  • Jose E. Almeida - Chairman of the Board, President & CEO

    Jose E. Almeida - Chairman of the Board, President & CEO

  • And also, we are continuing to see momentum from 2023 into 2024. So I feel cautiously optimistic about the momentum that we got in Q4 going into Q1. Of course, we look at many different factors when we are guiding. But I can tell you that based on the market growth, some of the demand that we're seeing, we feel very comfortable with Q1. And also, we have always had crescendo throughout the year, where we have product launches. We have 10 molecules launching in pharmaceutical. They're starting this quarter that we see ramping throughout Q2, Q3 and Q4. And also, there are some very important accounts that we -- is still closing on for the rest of the year that we will also boost our ability to do well in 2024.

    另外,我們也持續看到 2023 年的動能延續到 2024 年。因此,對於第四季(Q4)的動能進入第一季(Q1),我抱持審慎樂觀。當然,我們在提供指引時會考量許多不同因素。但我可以告訴你,基於市場成長、以及我們看到的一些需求,我們對 Q1 感到非常有把握。而且,我們一向在全年會有逐步走強的態勢,因為我們會有產品上市。我們在製藥領域有 10 個分子(molecules)將上市,從本季開始,並預期在 Q2、Q3 與 Q4 持續放量。此外,還有一些非常重要的客戶——我們仍在為今年其餘時間完成簽約,這也會提升我們在 2024 年表現良好的能力。

  • Unidentified Analyst

    Unidentified Analyst

  • Got it. And then if I could slip in a quick one. You talked about the capital equipment environment continuing to improve some pockets of weakness. What are you assuming for 2024 in the guidance? Are you expecting continued little bits of pockets of weakness? Or are you having that basically normalized over the course of the year?

    了解。那我再快速追問一個。你提到資本設備環境持續改善,但仍有一些疲弱的區塊。你們在 2024 年的指引中是如何假設的?你們預期仍會持續出現一些零星疲弱區塊?還是你們假設這些會在全年過程中基本回到正常?

  • Jose E. Almeida - Chairman of the Board, President & CEO

    Jose E. Almeida - Chairman of the Board, President & CEO

  • Most of our assumptions are large system -- medium to large systems continue to improve. We can see that, and we're going to see that slightly in Q1, but going into Q2, Q3 and Q4. There are pockets of softness in capital like always are, primarily smaller systems. Remember, interest rates are still very high and those affect the smaller systems. But for the majority of our customers, we're starting to see a recovery in capital when we feel really comfortable in 2024 that is recovering completely from what we saw in the beginning of -- end of '22 into '23.

    我們的大多數假設是:大型系統——中大型系統會持續改善。我們看得到這點,且在 Q1 會略有體現,但在 Q2、Q3 與 Q4 會更明顯。資本端一如既往會有一些疲弱區塊,主要是在較小型系統。請記得,利率仍然很高,而這會影響小型系統。但對我們大多數客戶而言,我們開始看到資本支出回升;我們對 2024 年非常有信心,認為資本端將完全從我們在 2022 年底到 2023 年初所看到的情況中復甦。

  • Clare Trachtman - VP of IR

    Clare Trachtman - VP of IR

  • Yes. And [Allen], just to add on to that. Similarly, I think we will see sequential improvement for capital orders within our CCS business every quarter this year, leading to orders being up on a year-over-year basis. And as mentioned in our prepared remarks, we saw a very similar trend kind of in 2023 as well. And then in the fourth quarter, we did see our orders up on a year-over-year basis. So we've been seeing this steady sequential improvement. And so we're going to build on that momentum as we go into 2024.

    是的。[Allen],我再補充一下。同樣地,我認為今年我們 CCS 業務的資本訂單將在每一季都呈現逐季改善,並帶動訂單在年對年基礎上轉為成長。如同我們在事先準備的講稿中提到的,我們在 2023 年也看到非常類似的趨勢。而在第四季,我們確實看到訂單年對年成長。因此,我們一直看到穩定的逐季改善。我們將在進入 2024 年時延續並強化這股動能。

  • Operator

    Operator

  • Matt Miksic of Barclays is on the line with a question.

    巴克萊(Barclays)的 Matt Miksic 在線上提問。

  • Matthew Stephan Miksic - Research Analyst

    Matthew Stephan Miksic - Research Analyst

  • Can you hear me okay?

    你們聽得到我嗎?

  • Jose E. Almeida - Chairman of the Board, President & CEO

    Jose E. Almeida - Chairman of the Board, President & CEO

  • Yes, we can.

    是的,我們聽得到。

  • Matthew Stephan Miksic - Research Analyst

    Matthew Stephan Miksic - Research Analyst

  • Great. So I had -- congrats on the solid results here and the pickup in the old Hillrom business. So I just have a question on the seasonality of that business. And also if you could maybe just to the extent of recurring revenues in that business. And I think we're used to a history there being capital driven, Q4 driven. But with some of the increase in sort of contracting around connected care and systems that -- I'm wondering, is that a mix of recurring revenue that we should see over time? Or you're starting to see a mix change in that business? Any color on that front would be super helpful.

    很好。我想說——恭喜你們交出穩健的成果,以及原 Hillrom 業務的回升。我有一個關於該業務季節性的問題。另外,如果可以的話,也請談談該業務經常性收入(recurring revenues)的程度。我想我們過去習慣它是以資本設備驅動、且第四季(Q4)驅動為主。但隨著在互聯照護(connected care)與系統方面的合約簽訂增加——我想了解的是:是否有一部分經常性收入的組合會隨時間推進而顯現?或者你們是否已開始看到該業務的組合正在改變?若能提供一些說明會非常有幫助。

  • Jose E. Almeida - Chairman of the Board, President & CEO

    Jose E. Almeida - Chairman of the Board, President & CEO

  • So we always have the seasonality. We see hospitals a little bit more cautious in the first quarter. And then as they get through the first quarter, they start spending the money that they have for the year and it culminates usually with a strong Q4 in terms of growth because a lot of spending gets done there. We try to, as much as possible, create more -- a less seasonality, but those things happen and our (inaudible). I think one important program we have in Baxter, as you noticed, is strength in our beds in the fourth quarter.

    我們一直都有季節性。我們看到醫院在第一季會比較謹慎一些。然後當他們度過第一季後,就會開始動用他們當年度的預算支出,通常會在第四季(Q4)達到高峰、帶來較強的成長,因為很多支出會在那時完成。我們會盡可能讓季節性降低、讓波動更小,但這些情況仍會發生,而我們的(聽不清)。我認為 Baxter 有一個重要的計畫,如你所注意到的,是我們在第四季床位產品的強勁表現。

  • We continue to go for some large accounts and conversions and we're starting to get some success there. When we bring Baxter together, what Baxter can do as one company is incredible for hospitals. So we feel that, that momentum is starting to kick in with accounts that are partially penetrated, going full blow into a Baxter account. We saw that with the conversion that we get this kind of launch in early 2025 in Northern Cal that we have large accounts and other things that we can see. So this is a really good momentum for Baxter. We can see that going.

    我們持續爭取一些大型客戶與轉換案(conversions),而且開始取得一些成果。當我們把 Baxter 整合在一起,Baxter 作為一家公司的能力對醫院而言是非常驚人的。因此,我們覺得這股動能正開始在那些我們已部分滲透的客戶上發酵,進一步全面轉為 Baxter 客戶。我們在北加州看到一個轉換案——我們會在 2025 年初進行這類啟動(launch),那裡有大型客戶以及其他我們看得到的機會。因此,這對 Baxter 來說是非常好的動能,我們看得到它正在延續。

  • But the first quarter is always, is always a much lighter quarter than the rest of the year. The revenue in terms of Front Line Care is a business that has less seasonality than the CCS business under HST. The reason is that it's more consistent with procurement in doctors' offices and monitors into hospital Med-Surg floors. So that brings less seasonality.

    但第一季一向——一向都比全年其他季度更淡。就 Front Line Care 的營收而言,這個業務的季節性比 HST 旗下的 CCS 業務更低。原因是它更符合醫師診所的採購節奏,以及監護設備進入醫院內外科病房(Med-Surg floors)的需求,因此季節性較低。

  • A business that is very predictable is our MPT business, which has been successfully growing, as you can see in 2023. 150 basis points above its market growth rate, driven tremendously by infusion systems as well as solutions, IV solutions. So that brings that business to a quite less seasonable, more repeatable. I hope I was able to answer your question.

    另一個非常可預測的業務是我們的 MPT 業務,正如你在 2023 年所看到的,它一直成功成長。其成長率比市場成長率高出 150 個基點,主要由輸注系統以及解決方案、靜脈輸液(IV)解決方案強力帶動。因此,這使得該業務季節性更低、可重複性更高。我希望我有回答到你的問題。

  • Joel T. Grade - Executive VP & CFO

    Joel T. Grade - Executive VP & CFO

  • Yes. If I could just add one thing to that. I mean I think the way to think about that HSD business over the course of the year and then just to build on what Joe said is that we're going to see, I'd say, sequential ramp up over the course of the year in that business. So I think the -- again, as Clare talked a little bit earlier, I mean there's going to be somewhat of a ramp up in sales that you're going to see, and that's particularly going to be applicable to that segment.

    是的。我再補充一點。我認為看待該 HSD 業務全年表現的方式——並在 Joe 的說法上再延伸——是我們會看到該業務在全年呈現逐季拉升。我想——同樣地,正如 Clare 先前稍早提到的——你會看到銷售有一定程度的逐步爬升,而這點特別會適用於該事業部門。

  • The other thing I would just say, you recall last year, Front Line Care had a fairly sizable amount of growth in 2023 as they worked through some of the backlog. There's a bit of an early headwind on that business during the first part of the year as well. So again, sequential ramp-up in that business is just I want to add out, Matthew, to that.

    另外我還想補充一點,你還記得去年,Front Line Care 在 2023 年因為處理部分積壓訂單而有相當可觀的成長。今年上半年該業務也會面臨一些較早出現的逆風。因此,再次強調,該業務的逐季爬坡,我只是想補充說明一下,Matthew。

  • Operator

    Operator

  • Vijay Kumar of Evercore ISI is on the line with a question.

    Evercore ISI 的 Vijay Kumar 在線上提問。

  • Vijay Muniyappa Kumar - Senior MD and Head of Medical Supplies & Devices and Life Science Tools & Diagnostics Team

    Vijay Muniyappa Kumar - Senior MD and Head of Medical Supplies & Devices and Life Science Tools & Diagnostics Team

  • Joe, maybe my first one for you. High level when I just look at the business ex-Kidney Care. 3% to 4%, that's a reasonable number, but it's still below Medtech, right? When I look at the utilization environment, what some of your peers are talking about. Like why is Baxter 3% to 4%? Are there any one-offs in that 3% to 4% ex-Kidney Care. When I look at the legacy Hillrom business, Q4 was really strong. Why should that business slow down if capital order book is turning around in fiscal '24?

    Joe,我第一個問題可能想請教你。從高層次來看,若只看不含 Kidney Care 的業務,3% 到 4% 是個合理的數字,但仍低於 Medtech,對吧?我看目前的使用量環境,以及一些同業在談的情況。為什麼 Baxter 只有 3% 到 4%?在不含 Kidney Care 的 3% 到 4% 裡,有沒有任何一次性因素?再看傳統的 Hillrom 業務,Q4 表現很強。若資本設備訂單簿在 2024 財年回溫,為什麼那個業務會放緩?

  • Jose E. Almeida - Chairman of the Board, President & CEO

    Jose E. Almeida - Chairman of the Board, President & CEO

  • Vijay, let me give you a perspective on 3% to 4% for this business. It's still growing above its market growth rate because we expect to be on the high end of that guidance. What makes that business go 100 basis points above that? We have, first of all, this business has pharmaceutical in it. We still have price erosion there, but pharmaceutical is going to be punching 4% to 5%. Our MPT is going to be between 3% and 4% and probably with the opportunity to go above that.

    Vijay,我先就這個業務 3% 到 4% 的成長給你一個觀點。它仍然高於其市場成長率,因為我們預期會落在該指引的高端。是什麼能讓該業務比那個水準再高 100 個基點?首先,這個業務包含製藥。我們在製藥仍有價格侵蝕,但製藥將會有 4% 到 5% 的成長。我們的 MPT 會在 3% 到 4% 之間,而且可能有機會高於此。

  • Now becomes HST. What is happening in HST? We have significant amount of launches going in at the end of '24 and '25. We have new monitors. We have new cardiology device and we continue to be successful on Progressa+. So a lot of that has to do with our -- to get to the 4% to 5%, it has to be new product launches in 2025, now for pharmaceutical. Because then you can see already it's making a difference to their growth rate.

    接著是 HST。HST 發生了什麼?我們在 2024 年底與 2025 年有大量新品上市。我們有新型監護儀。我們有新的心臟科裝置,而且我們在 Progressa+ 上持續成功。因此,要達到 4% 到 5%,很大一部分取決於我們在 2025 年的新產品上市,現在就製藥而言。因為你已經可以看到,這正開始對其成長率產生影響。

  • It's now for MPT, which is -- continues to do extremely well in Infusion Systems. We're going to have than 40% growth between '24 and '23 in our infusion pumps. It's going to be new products in HSV, primarily in Front Line Care and CCS with care communications, new versions of Voalte, there is the 3 new versions will be launched this year, as well as our new wireless communication device that we plan to launch in 2025. So monitors, wireless communication and cardiology, that is what's going to drive that business to go above 4%. And if we execute well, you will do it.

    再來是 MPT,該業務在輸注系統(Infusion Systems)持續表現非常好。我們的輸注幫浦在 2024 年相較 2023 年將成長超過 40%。HSV 的成長將來自新產品,主要在 Front Line Care,以及 CCS 的照護通訊(care communications),包括 Voalte 的新版本,今年將推出 3 個新版本;以及我們計畫於 2025 年推出的新無線通訊裝置。因此,監護儀、無線通訊與心臟科,將推動該業務超過 4%。如果我們執行得好,你們就會看到。

  • Joel T. Grade - Executive VP & CFO

    Joel T. Grade - Executive VP & CFO

  • I would also say too. If you think about the -- as we separate the Kidney business and we talk about later on in this year, having an investor event. What you're going to hear us talk about is how we think about capital allocation. How we think about the opportunity for, again, the portfolio ultimately too. Because think about, we have a lot of products with very high market share businesses. And so the opportunity to accelerate that growth is something we're going to talk about later on.

    我也想補充,如果你想想——當我們分拆腎臟業務,並在今年稍晚舉辦投資人活動時,你將會聽到我們談我們如何思考資本配置,以及我們如何看待整體投資組合的機會。因為想想看,我們有很多產品在各自市場中擁有非常高的市占率。因此,加速成長的機會,是我們稍後會談的重點。

  • But again, that's part of the benefit of the Kidney separation is the ability to actually really focus our capital allocation on accelerating the growth to the levels that you're thinking about there.

    但同樣地,腎臟業務分拆的其中一項好處,就是能夠真正把資本配置聚焦在把成長加速到你所期待的水準。

  • Vijay Muniyappa Kumar - Senior MD and Head of Medical Supplies & Devices and Life Science Tools & Diagnostics Team

    Vijay Muniyappa Kumar - Senior MD and Head of Medical Supplies & Devices and Life Science Tools & Diagnostics Team

  • Understood. And then maybe one on the guidance question. What is -- is inflation still a headwind to margins? What is price versus inflation and interest expense Q4? You didn't note the sequential step down in debt payments. Is that a sustainable number?

    了解。那再問一個關於指引的問題。通膨對毛利率仍是逆風嗎?價格相對於通膨的情況如何?以及 Q4 的利息費用?你們沒有提到債務償還的逐季下降。那是可持續的數字嗎?

  • Clare Trachtman - VP of IR

    Clare Trachtman - VP of IR

  • So you want me to -- I'll start with interest. What I would say, Vijay, on interest is that in the first half of the year, it's probably, I'd say, first quarter, probably similar. It steps up likely a little bit in the second quarter, and then we'll step up in the second half of the year. We are planning to pay down some low coupon debt in the second quarter.

    你希望我——我先從利息開始。Vijay,關於利息,我會說上半年大概——我想第一季可能差不多;第二季可能會小幅上升;然後下半年會再上升。我們計畫在第二季償還一些低票息債務。

  • And so right now, we're earning some cash -- or earning interest income on the cash that we have, and so that will go away in the second half of the year. So that's why you'll see a bit of a higher interest expense in the second half of the year as compared to the first half.

    而且目前我們手上的現金正在賺取一些利息收入,因此到下半年那部分會消失。所以你會看到下半年的利息費用相較上半年會略高。

  • Joel T. Grade - Executive VP & CFO

    Joel T. Grade - Executive VP & CFO

  • Yes. And on the debt paydown, I mean, again, we -- of the $3.7 billion of proceeds after tax we got from the sale of BPS, we actually used $2.8 million of that to pay down debt in the fourth quarter. Again, we have some debt coming due that's maturing in 2024 that we will use some of the rest of that for, particularly the Eurobond as Clare talked about. And then obviously, we have some debt maturing later in the year that we'll actually address at that point in time.

    是的。至於償債,我是說,再次強調——我們從出售 BPS 取得的稅後 37 億美元款項中,我們在第四季實際用其中 2.8 百萬美元來償還債務。同樣地,我們在 2024 年有一些到期債務,我們會用剩餘款項的一部分來處理,特別是 Clare 提到的歐元債(Eurobond)。然後很明顯地,我們在今年稍晚還有一些到期債務,我們會在那個時間點再處理。

  • Clare Trachtman - VP of IR

    Clare Trachtman - VP of IR

  • And then to your other question, kind of just on overall the inflationary environment and pricing. What I would say, and we referenced this earlier, is that our integrated supply chain team is executing on their margin improvement program. And so those programs and the savings we will generate this year will positively contribute to our margin expansion. So they will more than offset any sort of normalized inflation that we have.

    至於你另一個問題,關於整體通膨環境與定價。我會說——我們先前也提過——我們的整合供應鏈團隊正在執行其毛利改善計畫。因此,這些計畫以及我們今年將產生的節省,會對毛利擴張帶來正面貢獻,並且會超過抵銷我們所面臨的任何正常化通膨。

  • In addition, we are getting -- pricing will be a benefit this year as well. So we are getting pricing, particularly in markets outside the U.S., as well. So we are going after all of those -- our businesses are targeting price in all of those markets as well. So pricing will be positive for the year as well.

    此外,今年定價也會帶來助益。我們也正在取得定價,特別是在美國以外的市場。因此,我們的各項業務也在所有這些市場推動定價。所以今年定價也會是正面因素。

  • In terms of kind of all of those pieces, what I would say on the non-op side is that you have a positive on interest, but you will see that our tax rate is increasing. We did comment on that because of the implementation of Pillar Two FX. So we have some FX. I talked about it being kind of negative on the operating margin. So all in, our non-op is probably -- probably about a couple of cents negative impact for us on the year.

    就這些構成而言,我會說在非營運面,你會看到利息是正面,但我們的稅率會上升。我們確實提到這點,因為第二支柱(Pillar Two)外匯(FX)的實施。因此我們有一些 FX。我提到它對營業利益率會有些負面影響。綜合來看,我們今年的非營運項目對我們大概會有約幾美分的負面影響。

  • Operator

    Operator

  • Pito Chickering of Deutsche Bank Securities is on the line with a question.

    德意志銀行證券(Deutsche Bank Securities)的 Pito Chickering 在線上提問。

  • Philip Chickering - Research Analyst

    Philip Chickering - Research Analyst

  • Joel, like you've been in that seat for very long, but I just think a fresh set of eyes on the operations of Baxter. Can you walk us where you think the most margin upside is over the next several years? And what you need to do to hit those cost reductions. Any areas that you want to hit like procurement or any other sort of low-hanging fruit?

    Joel,你坐在這個位置的時間不算久,但我想你用新的視角看 Baxter 的營運。你能否帶我們了解一下,未來幾年你認為毛利率上行空間最大的地方在哪裡?以及要達成那些成本降低,你需要做些什麼?有沒有你想優先著力的領域,例如採購或其他比較容易摘取的果實?

  • Joel T. Grade - Executive VP & CFO

    Joel T. Grade - Executive VP & CFO

  • Sure. Absolutely. Thanks a lot for the question. Yes, I think one of the biggest opportunities we have from a margin perspective is to continue the work that we're doing in our independent supply chain group. I think the team has got a lot of really good margin improvement programs going that are designed specifically around things like automation. They're designed around things like how do we enhance our procurement abilities. They're around -- continuing around things about how do we optimize our network and some of the logistics opportunities.

    當然,絕對可以。非常感謝這個問題。是的,我認為從毛利率角度來看,我們最大的機會之一,是持續推進我們在獨立供應鏈團隊所做的工作。我認為團隊已經啟動了很多非常好的毛利改善計畫,這些計畫特別聚焦在例如自動化;也聚焦在如何提升我們的採購能力;以及——持續聚焦在如何優化我們的網路布局與一些物流方面的機會。

  • I think some of the areas that are the most impactful over time sit in that space, again -- and that's -- the team has gotten off to, again, a really good start on that. You've heard Clare talk about the fact that as we continue to see some inflationary pressures coming out, I think the work that they've done has gotten us to a place where we have the ability to offset that. But to continue the expansion of the margins, to your point, fall into some of those categories that I just referred to.

    我認為隨著時間推移,影響最大的領域就在那個範疇內,再次強調——而且——團隊在這方面已經有一個非常好的開端。你也聽到 Clare 提到,隨著我們持續看到一些通膨壓力消退,我認為他們所做的工作讓我們具備了抵銷通膨的能力。但要如你所說持續擴大利潤率,主要就落在我剛才提到的那些類別之中。

  • I think the other piece of some of you heard me say this already. We're not going to SG&A ourselves to prosperity. But nonetheless, there are still opportunities in that space as well around things like, again, how do we think about a shared services environment that actually allows for consistent execution of operations across the business.

    我想另一個重點,有些人可能已經聽我說過。我們不會靠把SG&A(銷售、一般及行政費用)一路砍到「繁榮」。但即便如此,在那個領域仍然有機會,例如,再次回到我們如何看待共享服務的環境,讓整個企業的營運能夠一致地執行。

  • And I know this is not a margin question, but the other part of what we're going to focus on heavily is our -- is cash that we will continue to -- how do we drive an improved use of working capital? How do we improve our cash conversion ratio again? I know that's not specifically what you asked. But again, that's going to be an area I see the opportunity.

    我知道這不是一個關於毛利率的問題,但我們另一個會重點聚焦的部分是——是現金;我們將持續——如何推動更好的營運資金運用?如何再次改善我們的現金轉換比率?我知道這不是你特別問的,但這確實是我看到的機會所在。

  • And what that all leads to is then the opportunity for us to continue to reinvest some of that back into our business around innovation, around new product development. And back to the question that was asked earlier, how do we continue to accelerate growth. That's what I call a flywheel that allows us to continue to grow, continue to invest and continue to grow, et cetera, et cetera, which is where we want to get to this company.

    而這一切最終帶來的,就是讓我們有機會把其中一部分再投資回到業務中,用於創新、用於新產品開發。回到先前有人問到的問題:我們如何持續加速成長。這就是我所說的飛輪,讓我們能夠持續成長、持續投資、再持續成長,等等、等等——這正是我們希望這家公司達到的狀態。

  • Philip Chickering - Research Analyst

    Philip Chickering - Research Analyst

  • Great. And then for a follow-up, you opened Pandora's box a little bit here by providing segment level margins for 4Q in 2023. Now we're going to be looking possibly to rebuild their models. Can you break out sort of the margins in each division for what you're seeing for 2024? And then a quick pump question here, how is market share for pumps in 4Q as you compete against next-gen pumps and any update on Novum?

    很好。接著追問一下,你們在這裡稍微打開了潘朵拉的盒子,因為你們提供了2023年第四季按事業部門的利潤率。現在我們可能要回頭重建模型。你能否拆分一下你們對2024年各事業部門所看到的利潤率大概會是什麼?另外一個關於幫浦的快問:在你們與下一代幫浦競爭之際,第四季幫浦的市占率如何?以及Novum有沒有任何更新?

  • Jose E. Almeida - Chairman of the Board, President & CEO

    Jose E. Almeida - Chairman of the Board, President & CEO

  • Let me start with the pumps and then Clare is going to answer the first part of your question. Yesterday, we just got awarded best-in-class KLAS for our Sigma Spectrum pump, which is a great honor. That pump continues to do a great job. Nonetheless, we're looking forward to get Novum approved. But in terms of market share, we continue to advance our market share. This year, we have 40-plus percent growth in our pumps versus last year. That's our forecast.

    我先從幫浦開始,然後Clare會回答你問題的第一部分。昨天,我們的Sigma Spectrum幫浦剛獲得KLAS同級最佳(best-in-class)的肯定,這是很大的榮譽。這款幫浦持續表現非常好。儘管如此,我們也期待Novum能獲得核准。至於市占率方面,我們持續提升市占。今年我們預估幫浦業務相較去年將成長40%以上。

  • So we continue to do well, and we look forward to continue to gain market share and now with a nice award to our pump. It's the seventh award that, that pump received since it was launched. So back to Clare now to answer the first part of your question.

    所以我們持續表現良好,也期待繼續提升市占率;而且我們的幫浦還拿到了一個很棒的獎項。這是該幫浦自上市以來獲得的第七個獎項。接下來交給Clare回答你問題的第一部分。

  • Clare Trachtman - VP of IR

    Clare Trachtman - VP of IR

  • Yes. Pito, in terms of the 2024 operating margin guidance, we aren't going to give that by segment. But obviously, all of our actions are aligned to improve both the segment and total Baxter margins. The one caveat I would point out is that within our Pharmaceuticals business, as you're aware, we did divest our BioPharma Solutions business last year. And so as a result, we entered into some MSAs, which will have a negative impact on the pharmaceutical margins and obviously on total Baxter margins for the year as we've now entered into the MSA. So you will see that impact in the pharmaceuticals margins.

    好的。Pito,關於2024年營業利潤率指引,我們不會按事業部門提供。不過很明顯,我們所有行動都與提升各事業部門以及Baxter整體利潤率的目標一致。我想提醒的一點是,在我們的製藥業務中,如你所知,我們去年已出售BioPharma Solutions業務。因此,我們簽訂了一些MSA(主服務協議),這將對製藥業務利潤率、以及今年Baxter整體利潤率造成負面影響,因為我們現在已進入MSA的執行期。所以你會在製藥業務利潤率中看到這個影響。

  • Operator

    Operator

  • Lawrence Biegelsen of Wells Fargo is on the line with a question.

    Wells Fargo的Lawrence Biegelsen在線上提問。

  • Unidentified Analyst

    Unidentified Analyst

  • It's [Lei] calling in for Larry. I just want to make sure I didn't miss it. Did you comment on the status of Novum IQ, the resubmission, and your thoughts on potential approval in '24? And I have a follow-up?

    我是[Lei],代替Larry來電。我只是想確認我沒有漏聽:你們有沒有評論Novum IQ的狀態、重新提交(resubmission)的進度,以及你們對於2024年可能獲批的看法?我還有一個追問。

  • Jose E. Almeida - Chairman of the Board, President & CEO

    Jose E. Almeida - Chairman of the Board, President & CEO

  • I didn't comment on the details, and we usually don't comment on anything that is with the FDA on behalf of the FDA. We can tell you that we answered all their questions. There's no other questions to be answered. All the documentation was submitted. So as always, this is at their side now to make a final decision on this.

    我沒有評論細節,而且我們通常不會代表FDA去評論任何正在FDA那邊審查的事項。我們可以告訴你的是:我們已回答他們所有問題,沒有其他問題需要再回答;所有文件都已提交。所以一如既往,現在就看他們那邊做出最終決定。

  • But as I said before and I said this about a month or so ago, I feel cautiously optimistic because there is nothing else for us to do. We answered all the questions. So there will be -- if that happen in '24, it will be a great thing. Nevertheless, we continue to gain market share for SIGMA SPECTRUM. As I said before, we just got an award, a best-in-class for that pump, and we're very happy, and we continue to be very busy quoting new accounts and competitive accounts, which we are actually winning with that pump.

    但正如我之前說過的——大約一個月前我也說過——我抱持審慎樂觀,因為我們已經沒有其他需要做的事了;我們回答了所有問題。所以——如果在2024年發生(獲批),那會是很棒的事。不過,我們仍持續提升SIGMA SPECTRUM的市占率。如我先前所說,我們剛拿到該幫浦的同級最佳獎項,我們非常高興;而且我們也持續非常忙碌地為新客戶與競品客戶報價,而我們確實正在用這款幫浦贏得這些案子。

  • Unidentified Analyst

    Unidentified Analyst

  • Got it. And my follow-up is just on your -- what you said about expectations for the 2 segments in '24. So Baxter ex-Renal, you expect 3% to 4% growth. Is that the right way to look at -- is that the right way to look at it longer term? And similarly, in the Renal business itself, you're expecting 1% to 2% decline this year. But once you adjust for the exits in China VBP, does Renal normalized to kind of low single-digit growth longer term?

    了解。我的追問是關於你們對2024年兩個事業群的預期。所以,Baxter(不含腎臟)你們預期成長3%到4%。這樣看——長期來看這樣看是對的嗎?同樣地,在腎臟業務本身,你們預期今年下滑1%到2%。但如果把中國VBP退出的影響調整回來,腎臟業務長期是否可「正常化」到低個位數成長?

  • Clare Trachtman - VP of IR

    Clare Trachtman - VP of IR

  • Yes. So [Lei], I'm going to go back to something that Joel mentioned earlier. We plan to have a Capital Markets Day later this year, where we will discuss our long-term expectations for the business. And -- but I think that both Joe and Joel have said that, while we're growing 3% to 4% through the introduction of new products, continued market expansion, our goal is to grow ahead of our weighted average market growth rate.

    是的。[Lei],我想回到Joel先前提到的一點。我們計畫在今年稍晚舉辦資本市場日(Capital Markets Day),屆時會討論我們對業務的長期預期。不過我想Joe和Joel都提到,雖然我們透過新產品導入、持續的市場擴張來達成3%到4%的成長,我們的目標是要成長快於我們加權平均的市場成長率。

  • So we do want to grow in advance of that. And so we'll be unveiling kind of those longer term. But no, I would say our goal is to accelerate growth off of that.

    所以我們確實希望成長能超前於此。我們會揭露那些較長期的目標;但不,我會說我們的目標是要在此基礎上加速成長。

  • With respect to Kidney Care, again, yes, we made $150 million of exits to that business, all aligned with our goal of enhancing profitability for that business post separation. So I think that what we want to ensure is that we're setting this business up for success as a stand-alone entity.

    至於腎臟照護(Kidney Care),同樣地,是的,我們對該業務做了1.5億美元的退出(exits),這些都與我們在分拆後提升該業務獲利能力的目標一致。所以我認為我們要確保的是,讓這項業務在作為獨立公司時能夠成功。

  • We also have the value-based procurement. There might be some follow-on to that in 2025. But I think the key is that the fundamentals for this business are improving. We're seeing solid patient growth. We're seeing a rebound in our Acute Therapies business. So I believe this business can accelerate at the levels -- that will grow at the levels that we're seeing once we make these adjustments.

    我們也有價值導向採購(value-based procurement),在2025年可能還會有一些後續。但我認為關鍵在於,這項業務的基本面正在改善。我們看到穩健的病患成長;我們看到急性治療(Acute Therapies)業務正在反彈。因此我相信,一旦我們做完這些調整,這項業務可以加速,並以我們所看到的水準成長。

  • Joel T. Grade - Executive VP & CFO

    Joel T. Grade - Executive VP & CFO

  • Yes. And I would just -- the question you asked, the -- we did again make purposeful decisions around exiting markets, exiting products. And so if you actually add that back from that $150 million we referred to earlier, I think, yes, you would find yourself in a place where there's a -- where the growth is actually in the low single digits.

    是的。我再補充一下——你問的問題——我們確實再次做出有目的的決策,包含退出某些市場、退出某些產品。所以如果你把我們先前提到的那1.5億美元加回去,我想,是的,你會發現自己會落在一個——成長其實是在低個位數的區間。

  • Operator

    Operator

  • Matt Taylor of Jefferies is on the line with a question.

    Jefferies的Matt Taylor在線上提問。

  • Matthew Charles Taylor - Equity Analyst

    Matthew Charles Taylor - Equity Analyst

  • I know you noted some progress on pricing. I was wondering if you could comment on that in your expectations for pricing in '24. And any updates on some of those bigger contracts that you've talked about in the past and your opportunities to reprice solutions, dialysis, nutrition, et cetera?

    我知道你們提到定價方面有一些進展。我想請你們評論一下你們對2024年定價的預期。另外,關於你們過去談到的一些較大型合約,有沒有更新?以及你們在重新定價解決方案、透析、營養等方面的機會?

  • Joel T. Grade - Executive VP & CFO

    Joel T. Grade - Executive VP & CFO

  • Yes. Sure. So we did make progress in pricing in 2023. And some of that was -- were temporary in nature in the sense that we had some adds to pricing that will again fall off at the end of the year here. But we do have part of our growth and our margin expansion in 2024, that is continuing progress in the areas of pricing.

    好的,當然。我們在2023年的定價確實有進展。其中一部分——屬於暫時性的,因為我們有一些加價項目會在今年年底到期、之後就會消失。但在2024年的成長與利潤率擴張中,有一部分來自於我們在定價領域持續取得進展。

  • And I think one of the things that we've talked about is -- just as a reminder, some of the contracts with the GPOs that we've signed, we've made continued progress on them. That actually doesn't kick in until 2025. So just to just to remind you of that, that that's not part of what we're talking about in terms of progress.

    我想我們談過的一件事是——提醒一下,我們與GPO(集團採購組織)簽署的一些合約,我們在其上持續取得進展。但那其實要到2025年才會生效。所以再提醒你一次,那並不是我們在談的、所謂進展的一部分。

  • But again, the team has made solid progress in terms of continuing to take pricing in 2024. And the other thing I would say that we've done a good job already and are going to continue to do an even better job of, is to give ourselves the opportunities to actually have indexes within our pricing that allow us more flexibility to pass along costs that are coming into our world that we have historically struggled to pass along to our customers. Again, we're making progress in that area as well.

    但再說一次,團隊在 2024 年持續推進價格調整方面已取得紮實進展。另一點我想說的是,我們已經做得不錯、而且將持續做得更好的是:在我們的定價中納入指數化機制,讓我們更有彈性把進入我們業務環境的成本轉嫁出去;而這些成本在過去我們一直難以轉嫁給客戶。再一次,我們在這方面也正在取得進展。

  • So generally speaking, as Clare talked about, our expansion margins really is focused around some of the operational work that we're doing, but also, again, our pricing progress continues in 2024, and we look to accelerate that further in 2025 and beyond.

    因此,整體而言,正如 Clare 所談到的,我們的擴張毛利率主要聚焦在我們正在推動的一些營運工作上;但同樣地,我們在 2024 年的定價進展仍在持續,我們也希望在 2025 年及之後進一步加速。

  • Matthew Charles Taylor - Equity Analyst

    Matthew Charles Taylor - Equity Analyst

  • So I just ask a follow-up. I mean when can we hear more about the bigger contracts? Are you going to talk about that throughout the year? And can you comment at all on the kind of opportunities you have with some of those contracts, what's the order of magnitude of pricing you could get?

    我再追問一下。也就是說,我們何時能聽到更多關於較大型合約的資訊?你們會在全年持續談這件事嗎?另外,你們能否評論一下這些合約帶來的機會大概是什麼樣子,你們可能取得的定價幅度量級大概是多少?

  • Jose E. Almeida - Chairman of the Board, President & CEO

    Jose E. Almeida - Chairman of the Board, President & CEO

  • We are making great progress. We're in the middle of doing it. Once these contracts are signed, the next steps for us to secure the IDNs underneath them and Baxter do well on that. We are well poised to take that action. We are feeling quite comfortable where we are today in terms of signing these agreements. We're not going to tell exactly the status of -- where we are signing them for competitive reasons, neither the volume of dollars.

    我們正在取得很大進展。我們正在進行當中。一旦這些合約簽署完成,我們接下來的步驟就是在其下方爭取並鎖定 IDN,而 Baxter 在這方面做得很好。我們已具備充分條件採取該行動。就目前簽署這些協議而言,我們對現況感到相當有信心。出於競爭因素,我們不會透露確切的狀態——也就是我們簽到哪一步——也不會透露金額規模。

  • So you need to think about this as value. Value is -- dropping profit to the bottom line is value. That will be achieved with pricing and volume. Volume is important to us, the size of our plants. So we're getting a combination of both is the important thing for us. So our focus price is always important because the amount of headwind that we had in 2022, of course.

    所以你需要把這件事視為「價值」。價值是——把利潤落到最終損益表就是價值。這將透過定價與銷量來達成。銷量對我們很重要,因為我們工廠的規模。因此,對我們而言,重要的是兩者的組合。所以我們對價格的關注始終很重要,因為我們在 2022 年承受了那麼大的逆風,當然。

  • So we are considering that, but also expansion of market share is important to us as well because we have capacity and have been serving the market very well. So think about our objective in 2024 into 2025 is to continue to add value and significant accretion potentially to the bottom line by getting those contracts signed, but we are in good position.

    因此我們會把這點納入考量;但同時,擴大市占率對我們也很重要,因為我們有產能,且一直以來都把市場服務得很好。所以請把我們 2024 進入 2025 年的目標理解為:透過把這些合約簽下來,持續創造價值,並可能對最終損益帶來顯著增益;而我們目前處於有利位置。

  • Joel T. Grade - Executive VP & CFO

    Joel T. Grade - Executive VP & CFO

  • And we're not going to give specific details on the pricing or volume, as Joe referenced. So just think about that as guidance that we ultimately give on margins and volume growth will be inclusive of the progress we'll make with those contracts.

    而且,正如 Joe 所提到的,我們不會提供定價或銷量的具體細節。所以請把它視為:我們最終在毛利率與銷量成長方面所給出的指引,將會包含我們在這些合約上取得的進展。

  • Operator

    Operator

  • Danielle Antalffy of UBS is on the line with a question.

    UBS 的 Danielle Antalffy 在線上提問。

  • Danielle Joy Antalffy - Analyst

    Danielle Joy Antalffy - Analyst

  • And just a quick question on sort of what the longer-term focus is post Kidney Care? I assume we'll get some more color here once we have the pre-spin Analyst Day. But just at a high level, Joe and Joel, curious about where you see the most opportunities to improve whether organically or inorganically from an R&D perspective? And just longer term, i.e., over the next few years, where you think Baxter will be most focused and investing behind?

    我有個簡短問題,關於腎臟照護(Kidney Care)分拆之後的長期重點會是什麼?我想我們在分拆前的分析師日(pre-spin Analyst Day)應該會得到更多資訊。但就高層次而言,Joe 和 Joel,我想了解你們認為從研發角度看,無論是有機或無機成長,在哪些地方最有機會改善?以及更長期來看,也就是未來幾年,你們認為 Baxter 最會聚焦並加大投資在哪些領域?

  • Jose E. Almeida - Chairman of the Board, President & CEO

    Jose E. Almeida - Chairman of the Board, President & CEO

  • So Danielle, we're thinking about the strategy and the overarching imperative of this strategy is to advance and significantly improve the intrinsic value of the company. And we're going to do that organically and eventually inorganically as well with some tuck-ins and strategic acquisitions that will supplement some of our business. But -- so in the organic side to drive that, that intrinsic value multiplier is innovation, acceleration of innovation, expansion of our commercial footprint in areas that we currently don't participate well, as well as doubling down in operations excellence in all of our -- in all aspects of Baxter from the plants all the way to our back office.

    Danielle,我們正在思考策略,而這項策略的總體核心要務是推進並顯著提升公司的內在價值。我們會先以有機方式來做,並且最終也會透過無機方式來做,包括一些補強型(tuck-in)與策略性併購,以補充我們的部分業務。但——在有機面向,為了推動並放大內在價值的乘數,我們的重點是創新、加速創新、在我們目前參與度不足的領域擴大商業版圖,以及在 Baxter 的各個面向加倍投入營運卓越——從工廠一路到後勤辦公室。

  • So creating value in all parts of the company. So we can take some of that money, reinvest modestly in research and development and continue to accelerate the innovation. And the innovation, all of this is going to be done with a significant amount of importance to capital allocation, meaning where money goes inside of the company, how much is share buyback.

    也就是在公司各個部分創造價值。如此一來,我們可以把其中一部分資金拿出來,適度再投資於研發,並持續加速創新。而所有這些工作都會在資本配置高度重要的前提下進行,也就是資金在公司內部的去向,以及回購股票的規模等。

  • So this is a post spin when we are looking at a different debt structure and a different company past that. So think about our strategy, to accelerate innovation, accelerate penetration in commercial areas. We're not like alternate sites of care, ASCs. Those are the drivers of our organic growth, and that should drive a request for a multiplier on our intrinsic value as a company.

    這是在分拆之後,當我們面對不同的負債結構與不同的公司樣貌時所要做的思考。因此,請把我們的策略理解為:加速創新、加速在商業領域的滲透。我們不像——例如替代照護場域(alternate sites of care)、ASC(門診手術中心)。這些是我們有機成長的驅動因素,而這也應該促使市場對我們作為一家公司的內在價值給予更高的乘數。

  • Clare Trachtman - VP of IR

    Clare Trachtman - VP of IR

  • And Danielle, just to follow on and specific to kind of Kidney Care. What I would say is within Kidney Care, and obviously, Chris Toth will elaborate more on this. But they're going to focus on continuing to increase PD penetration globally. Really focusing on how do they enhance this digitally as well and what digital capabilities are out there to really help both clinicians and patients advance that therapy.

    Danielle,再補充一下,並特別針對腎臟照護(Kidney Care)。我想說的是,在腎臟照護內部——當然 Chris Toth 會更詳細說明——他們將聚焦於持續提升 PD(腹膜透析)在全球的滲透率。也會真正聚焦於如何在數位化方面加以強化,以及有哪些數位能力可以真正協助臨床醫師與病患推進該療法。

  • In addition, within the acute therapies business, I think they'll continue to build upon the continued renal replacement therapy and broaden into more multi-organ support therapies as well. So I think that they have a strategy there that they'll continue to build upon and execute as a stand-alone entity.

    此外,在急性治療(acute therapies)業務方面,我認為他們會持續在連續性腎臟替代治療(continued renal replacement therapy)上深化,並進一步拓展到更多多器官支持治療(multi-organ support therapies)。因此我認為他們在那裡有一套策略,將會作為一家獨立公司持續深化並執行。

  • Joel T. Grade - Executive VP & CFO

    Joel T. Grade - Executive VP & CFO

  • Yes. And I just think what Joe said and what Clare has talked about is just reinforcement of the strategic rationale for the separation that then allows us and Kidney, frankly, to both focus their capital allocation on those areas that really accelerate their growth. And as Joe said, I see that (inaudible) debt is at a level that we've targeted to actually reinforce this idea that we're going to have both organic and inorganic growth opportunities ahead of us.

    是的。我也認為 Joe 所說的,以及 Clare 所談到的,都是在強化這次分拆的策略性理由;而這也讓我們與腎臟業務坦白說都能把資本配置聚焦在那些真正能加速各自成長的領域。正如 Joe 所說,我認為(聽不清)負債已在我們所設定的目標水準,這其實是在強化這個想法:我們未來同時會有有機與無機的成長機會。

  • Operator

    Operator

  • Ladies and gentlemen, this concludes today's conference call with Baxter International. Thank you for participating.

    各位女士、先生,今天 Baxter International 的電話會議到此結束。感謝各位參與。